北大医药：阿普米司特片获药品注册证书

Core Viewpoint - The company received approval from the National Medical Products Administration for the drug Apremilast tablets, which are intended for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] Company Summary - The approval of Apremilast tablets marks a significant milestone for the company, expanding its product portfolio in the dermatology sector [1] - This drug is specifically aimed at treating adult patients with moderate to severe plaque psoriasis, indicating a targeted approach to addressing this skin condition [1] Industry Summary - The approval aligns with the growing demand for effective treatments for psoriasis, a chronic skin condition affecting a substantial portion of the population [1] - The introduction of Apremilast tablets may enhance competition within the dermatology market, particularly among companies offering psoriasis treatments [1]